Importantly, targeting renal ANGPTL4 with antisense oligonucleotides (ASOs) has shown promising protective effects against fibrosis in diabetic kidneys, paving the way for innovative therapeutic strategies to combat diabetic kidney disease and other fibrotic disorders. The gene discussed is ANGPTL4; the disease is diabetic kidney disease.